Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Niraparib Neoadjuvant in Unresectable Ovarian Cancer
NCT04507841Phase 2Active, not recruiting
- Sponsor
- Tongji Hospital
- Start
- Jan 2021
- Primary completion
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of niraparib in ovarian cancer, sponsored by Tongji Hospital. Started Jan 2021; status: active, not recruiting.
02
Drugs
niraparib
03
Conditions
ovarian cancer
Beyond the preview
Go deeper on NCT04507841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04507841.